# Corvus Pharmaceuticals

Source: https://onco.cc/companies/corvus-pharmaceuticals/  
OnCo record `corvus-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Corvus Pharmaceuticals is a Californian biotech whose oral ITK inhibitor soquelitinib rebalances T cells, with a registrational trial in relapsed T-cell lymphoma and studies in atopic dermatitis.

## Summary

Corvus Pharmaceuticals develops soquelitinib (CPI-818), a selective covalent inhibitor of interleukin-2-inducible T-cell kinase (ITK) that blocks malignant T cells and steers helper T cells towards a Th1 profile. It is in a registrational phase 3 trial in relapsed peripheral T-cell lymphoma and in phase 1 trials in atopic dermatitis. The company also developed the adenosine A2A antagonist ciforadenant and the CD73 antibody mupadolimab.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Corvus Pharmaceuticals, Inc.; NASDAQ:CRVS
- Tags: drug-maker
- HQ: Burlingame, California
- Type: biotech
- Website: https://www.corvuspharma.com/
- Ticker: NASDAQ:CRVS

## Sources

- Official website: https://www.corvuspharma.com/

## Connected records

- drugs: [Soquelitinib](https://onco.cc/drugs/soquelitinib/)

---
JSON: https://onco.cc/api/v1/entities/corvus-pharmaceuticals.json